(rivaroxaban)
This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
XARELTO® (rivaroxaban)
Medical Information
XARELTO - Reversal Agents in Human Studies - Andexanet alfaa (PRT064445) - Phase 2 Study
Last updated : 05/16/2024
A phase 2 study in healthy subjects confirmed a dose-dependent decrease in anti–factor Xa activity and a return of anti–factor Xa activity to placebo levels approximately 2 hours after treatment.1
>10%
>10% of AEs were infusion-related reactions and postural dizziness.1
0
Thrombotic events and serious or severe AEs1aAndexxa® (coagulation factor Xa [recombinant], inactivated-zhzo) is a product of AstraZeneca. Please refer to the Andexxa Prescribing Information for complete product information or call AstraZeneca at 1-800-236-9933.
AE, adverse event.
Reference
Show Hide
1. Crowther M, Mathur V, Kitt M, et al. A phase 2, randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for FXa inhibitors. Poster presented at: The 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 6-10, 2013; New Orleans, LA.
